Back to home
DEEP DIVEApril 6, 2026·10 min read
The Actinium-225 Problem: Radiopharmaceuticals' $450M Supply Chain Bet
TerraPower Isotopes' $450M Ac-225 production facility targets the critical bottleneck constraining alpha-emitting radiopharmaceutical development. We map the isotope supply chain, the physics of alpha vs beta emitters, and which clinical programs are supply-gated.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.